Prognosis of MAFLD vs. NAFLD and implications for a nomenclature change
- PMID: 34464658
- DOI: 10.1016/j.jhep.2021.08.020
Prognosis of MAFLD vs. NAFLD and implications for a nomenclature change
Keywords: MAFLD; NAFLD; NASH; metabolic dysfunction-associated fatty liver disease; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis.
Conflict of interest statement
Conflict of interest Vincent Wong served as a consultant or advisory board member for 3V-BIO, AbbVie, Allergan, Boehringer Ingelheim, Echosens, Gilead Sciences, Inventiva, Merck, Novartis, Novo Nordisk, Pfizer, ProSciento, Sagimet Biosciences, TARGET PharmaSolutions, and Terns; and a speaker for Abbott, AbbVie, Echosens, Gilead Sciences, and Novo Nordisk. He has received a research grant from Gilead Sciences, and is a co-founder of Illuminatio Medical Technology Limited. JVL reports grants and personal fees from AbbVie, Gilead Sciences and MSD; personal fees from CEPHEID, GSK, Genfit, Intercept, and Janssen, outside the submitted work. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
One not like the other: The weakness of the blood sugar-MAFLD analogy.J Hepatol. 2022 Feb;76(2):482-484. doi: 10.1016/j.jhep.2021.10.010. Epub 2021 Oct 20. J Hepatol. 2022. PMID: 34678406 No abstract available.
Comment on
-
The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease.J Hepatol. 2021 Aug;75(2):454-461. doi: 10.1016/j.jhep.2021.05.003. Epub 2021 May 19. J Hepatol. 2021. PMID: 34019941
-
Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.J Hepatol. 2021 Dec;75(6):1284-1291. doi: 10.1016/j.jhep.2021.07.035. Epub 2021 Aug 8. J Hepatol. 2021. PMID: 34380057
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical